Venrock logo

Venrock

Crunchbase
Pitchbook
Crunchbase

Deals on record

11

Common Fundraising Type

Series B

Timberlyne Therapeutics logo
Timberlyne Therapeutics

Biopharmaceutical

Venrock Healthcare Capital Partners logo
Lilly Asia Ventures logo
Braidwell logo
Boyu Capital logo
Bain Capital Life Sciences logo
Abingworth logo
3H Health Investment logo

Timberlyne Therapeutics is a biopharmaceutical company developing novel therapies for autoimmune disorders, focusing on advancing a monoclonal antibody targeting CD38.

Series A
$180M
01/10/2025
Article
Adcendo logo
Adcendo

Biotech

TCGX logo
Ysios Capital logo
Venrock Healthcare Capital Partners logo
Surveyor Capital logo
RA Capital Management logo
Pontifax Venture Capital logo
Novo Holdings logo
Logos Capital logo

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Series B
$135M
11/25/2024
Article
Metsera logo
Metsera

Biopharmaceutical

Venrock logo
Wellington Management logo
T. Rowe Price logo
SymBiosis logo
SoftBank logo
Newpath Partners logo
Janus Henderson logo
GV logo

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Series B
$215M
11/13/2024
Article
Scope3 logo
Scope3

Sustainability

Virgo Strategic Investments logo
Venrock logo
Room40 Ventures logo
GV logo
Craft Ventures logo
Aperiam Ventures logo

Scope3 provides sustainability solutions to reduce carbon emissions in the media, advertising, and AI industries.

Equity
$25M
10/10/2024
Article

Suki is an AI technology company that streamlines administrative tasks for healthcare clinicians by offering products that integrate with major EHR systems.

Series D
$70M
10/10/2024
Article
Candid Therapeutics logo
Candid Therapeutics

Biotechnology

Venrock Healthcare Capital Partners logo
Vida Ventures logo
TCGX logo
Third Rock Ventures logo
Soleus Capital logo
Samsara BioCapital logo
Redmile Group logo
Polaris Innovation Fund logo

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Equity
$370M
09/09/2024
Article
Vanilla logo
Vanilla

Estate planning

Venrock logo
Vanguard logo
Insight Partners logo
Edward Jones Ventures logo
Alumni Ventures logo

Vanilla provides estate planning software with embedded AI technology to a diverse range of clients, from small RIAs to major financial firms.

Equity
Undisclosed
08/15/2024
Article
Zero Networks logo
Zero Networks

Cybersecurity

Zero Networks is a cybersecurity firm that offers a fully automated SaaS platform employing zero trust principles to restrict user and machine access to only necessary assets and facilitate secure remote connections.

Series B
$20M
12/13/2023
Article
RefleXion Medical logo
RefleXion Medical

Therapeutic Oncology

Venrock logo
TPG logo
T.Rowe Price Associates logo
Square Point Capital logo
Pictet logo
Pfizer Ventures logo
Johnson & Johnson Innovation logo
Hillenbrand logo

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Equity
$105M
11/15/2023
Article
MBrace Therapeutics logo
MBrace Therapeutics

Biopharmaceutical

Venrock logo
Cowen Healthcare Investments logo
Avidity Partners logo
Alta Partners logo
TPG logo

MBrace Therapeutics is a biopharmaceutical company developing a lead antibody-drug conjugate (ADC) candidate, MBRC-101, targeting the EphA5 receptor tyrosine kinase present in various cancers, with the recent completion of an $85 million Series B financing round.

Series B
$85M
11/14/2023
Article
Scope3 logo
Scope3

Sustainability

GV logo
Venrock logo
Room40 Ventures logo

Scope3 provides sustainability solutions to reduce carbon emissions in the media, advertising, and AI industries.

Series B
$20M
10/12/2023
Article